Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04362189 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19
A Phase 2 study, sponsored by Hope Biosciences Research Foundation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT04362189 is a Phase 2 study that was terminated before completion, run by Hope Biosciences Research Foundation. The registered enrollment target is 48 participants.
The verdict
NCT04362189, a Phase 2 study, was terminated before completion, sponsored by Hope Biosciences Research Foundation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as treatment for patients suspected to have COVID-19. The study purpose is to evaluate the safety and efficacy of four IV infusions of either placebo or HB-adMSCs in subjects with COVID-19.
Interventions
- OTHER Placebo
- BIOLOGICAL HB-adMSC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2020-06-30 |
| Est. Completion | 2021-09-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04362189
The ClinicalTrials.gov registry entry for NCT04362189 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hope Biosciences Research Foundation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04362189 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04362189 about?
NCT04362189 is a clinical study titled "Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19". Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) as treatment for patients suspected to have COVID-19. The study purpose is to evaluate the safety and efficacy of four IV infusions of eit...
What is the current status of trial NCT04362189?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2020-06-30. Estimated completion is 2021-09-30.
What interventions are being tested in trial NCT04362189?
The interventions under investigation include: Placebo (OTHER), HB-adMSC (BIOLOGICAL).
Who is sponsoring clinical trial NCT04362189?
This trial is sponsored by Hope Biosciences Research Foundation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.